Here’s What’s Behind The Hottest Battleground Stock in Cancer Treatment [The Motley Fool]
Cel-Sci Corporation (CVM)
NASDAQ:AMEX Investor Relations:
cel-sci.com/investor_relations.html
Company Research
Source: The Motley Fool
CEL-SCI(NYSEMKT:CVMshort-sellersMeanwhile, phase topline results from the company's only prominent candidate, Multikine (leukocyte injection for the treatment of cancer in the oral cavity and soft palate), is set to be released in May. The company's fate is entirely dependent on the success of Multikine, as it is currently pre-revenue and has little cash on hand to fund further expenses.If it becomes approved, the drug has a total addressable market of over $ billion in the U.S. alone, as it treats a subset of head and neck cancer. Moreover, CEL-SCI has a partnership withTeva Pharmaceutical IndustriesNYSE:TEVAImage Source: Getty ImagesWhat is Multikine?Multikine is CEL-SCI's experimental injection comprised of cytokines (small proteins that instruct white blood cells to destroy foreign pathogens) designed to elicit the body's own immune system to produce antibodies to destroy cancerous cells, a process known as immunotherapy. Although cytokines are well documented to produce active i
Show less
Read more
Impact Snapshot
Event Time:
CVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVM alerts
High impacting Cel-Sci Corporation news events
Weekly update
A roundup of the hottest topics
CVM
News
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- CEL-SCI Appoints Mario Gobbo to Its Board of DirectorsBusiness Wire
- CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology [Yahoo! Finance]Yahoo! Finance
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyBusiness Wire
- CEL-SCI Co. (NYSE: CVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
CVM
Sec Filings
- 4/23/24 - Form 3
- 4/23/24 - Form 4
- 4/23/24 - Form 4
- CVM's page on the SEC website